How have ASND shares performed this year?

Ascendis Pharma A/S's stock was trading at $125.95 at the beginning of the year. Since then, ASND stock has increased by 16.4% and is now trading at $146.59. View the best growth stocks for 2024 here .

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) EPS for the quarter, topping the consensus estimate of ($2.60) by $1.13. The biotechnology company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.60 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative trailing twelve-month return on equity of 16,574.15%.

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's top institutional investors include Avoro Capital Advisors LLC (7.21%), Massachusetts Financial Services Co. MA (2.94%), Sofinnova Investments Inc. (1.26%) and Fred Alger Management LLC (0.53%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include AbbVie (ABBV) , Alexion Pharmaceuticals (ALXN) , Neurocrine Biosciences (NBIX) , ACADIA Pharmaceuticals (ACAD) , BioMarin Pharmaceutical (bmrn) , Gilead Sciences (GILD) and Incyte (INCY) .

Top-Rated StocksTop-Rated

NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

$146.59

+7.02 (+5.03%)

(As of 09/17/2024 ET)

Compare

Get Ascendis Pharma A/S alerts:

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Advanced Chart

Get Ascendis Pharma A/S alerts:

Key Stats

Today's Range: $138.82
▼
$148.92
50-Day Range: $112.93
▼
$140.80
52-Week Range: $85.29
▼
$161.00
Volume: 1.99 million shs
Average Volume: 435,695 shs
Market Capitalization: $8.54 billion
P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $193.77
Consensus Rating: Moderate Buy

Company Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 68th Percentile

Ascendis Pharma A/S scored higher than 68% of companies evaluated by MarketBeat, and ranked 336th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Consensus Rating
Ascendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Ascendis Pharma A/S has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Ascendis Pharma A/S's stock forecast and price target.

Earnings Growth
Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($6.83) to ($3.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ascendis Pharma A/S is -15.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ascendis Pharma A/S is -15.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Read more about Ascendis Pharma A/S's valuation and earnings.

Percentage of Shares Shorted
6.04% of the outstanding shares of Ascendis Pharma A/S have been sold short.
Short Interest Ratio / Days to Cover
Ascendis Pharma A/S has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Ascendis Pharma A/S has recently decreased by 4.61%, indicating that investor sentiment is improving.

Dividend Yield
Ascendis Pharma A/S does not currently pay a dividend.
Dividend Growth
Ascendis Pharma A/S does not have a long track record of dividend growth.

Percentage of Shares Shorted
6.04% of the outstanding shares of Ascendis Pharma A/S have been sold short.
Short Interest Ratio / Days to Cover
Ascendis Pharma A/S has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Ascendis Pharma A/S has recently decreased by 4.61%, indicating that investor sentiment is improving.

News Sentiment
Ascendis Pharma A/S has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 32 news articles for Ascendis Pharma A/S this week, compared to 5 articles on an average week.
Search Interest
13 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Insider Buying vs. Insider Selling
In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.
Read more about Ascendis Pharma A/S's insider trading history.

Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Stock News Headlines

Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed by Oppenheimer

September 18 at 4:45 AM | americanbankingnews.com

Ascendis Challenges BioMarin, But Market Response Seems Excessive

September 17 at 5:15 PM | seekingalpha.com

I’m giving you the name of this investment for free

In this video I reveal one of the most powerful wealth secrets in American history. One that has been buried in America’s legal system for the last 150 years. But I believe this secret could also help you reclaim your dignity and freedom before it’s all taken away from you.

September 18, 2024 | Porter & Company (Ad)

Buy Rating on Ascendis Pharma as TransCon CNP Triumphs in Trials, with Raised Target Price to $207

September 17 at 5:13 PM | markets.businessinsider.com

Oppenheimer Sticks to Their Buy Rating for Ascendis Pharma (ASND)

September 17 at 5:13 PM | markets.businessinsider.com

Ascendis Pharma A/S's (ASND) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

September 17 at 5:31 AM | americanbankingnews.com

Ascendis Pharma A/S ADRs Rise 15% on Trial Data for Achondroplasia Treatment

September 16 at 3:17 PM | marketwatch.com

Ascendis Pharma Receives Buy Rating Amid Positive Phase 3 Results for TransCon CNP

September 16 at 3:17 PM | markets.businessinsider.com

See More Headlines

ASND Stock Analysis - Frequently Asked Questions

: Ascendis Pharma A/S's stock was trading at $125.95 at the beginning of the year. Since then, ASND stock has increased by 16.4% and is now trading at $146.59.
View the best growth stocks for 2024 here.
: Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) EPS for the quarter, topping the consensus estimate of ($2.60) by $1.13. The biotechnology company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.60 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative trailing twelve-month return on equity of 16,574.15%.
: Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.
: Ascendis Pharma A/S's top institutional investors include Avoro Capital Advisors LLC (7.21%), Massachusetts Financial Services Co. MA (2.94%), Sofinnova Investments Inc. (1.26%) and Fred Alger Management LLC (0.53%).
: Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
: Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD) and Incyte (INCY).